OXC-101 as a novel therapy for AML will be presented at 18[th] Annual Congress of International Drug Discovert Science & Technology, Amsterdam 12-14 July, 2023

Oxcia’s CEO Ulrika Warpman Berglund has been invited to present “OXC-101: A Novel Way to Treat Acute Myeloid Leukemia by Inducing Mitotic Arrest, ROS and Oxidative Damage” at the 18th Annual Congress of International Drug Discovery Science & Technology (IDDST) conference, Amsterdam, the Netherlands, July 12-14, 2023.

OXC-101 is a mitotic MTH1 inhibitor, with a unique synergistic dual mechanism of action. It arrests cancer cells in mitosis by disturbing microtubule polymerization, thereby accumulating ROS which in turn generates e.g. oxidized nucleotides. By inhibiting the enzyme MTH1, OXC-101 incorporates more oxidized nucleotides into DNA resulting in DNA damage and the cancer cell dies via apoptosis and mitotic catastrophe. Hematological cancers are highly responsive to OXC-101 treatment. Importantly, OXC-101 has been demonstrated to kill primary human AML blast cells as well as chemotherapy resistant leukemic stem cells. The latter are often responsible for AML progression. OXC-101 significantly improves survival in different AML disease models and is an excellent combination partner to the standard of care treatment of AML. The preclinical data supports that OXC-101 is a promising novel anticancer agent for AML, providing rationale for the on-going clinical phase 1 trial in advanced hematological cancers. Oxcia recently obtained a Swelife/MedTech4Health grant together with Karolinska University Hospital Örebro University Hospital and Karolinska institutet to further explore the clinical benefit and safety of OXC-101 in refractory/relapsed AML patients at the recommended phase 2 dose.

The IDSST congress focuses on drug discovery, practical pharmaceutical science, clinical studies, translational medicine and new drugs in the pipeline. The meeting is intended for industrial executives, principle investigators, and investors with the aim that constructive discussions will create ideas to translate new discoveries into better clinical practice and application.

Full program can be found: https://www.iddst.com/iddst2023europe/ScientificProgram.asp

For more information contact:

Ulrika Warpman Berglund, CEO, Oxcia AB (publ)

Telephone: +46 (0) 73 270 9605

Briefly about Oxcia

Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101  is in early clinical development as novel cancer therapy. OXC-201  is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.

More information about Oxcia is available at www.oxcia.com